2025-11809Notice

FDA Guidance Focuses on Lyme's Tell-Tale Expanding Rash

Published Date: 6/26/2025

Notice

Summary

The FDA just released final guidance to help drug makers create better treatments for early Lyme disease, especially when it shows up as a rash called erythema migrans. This update affects companies developing Lyme disease drugs and aims to speed up safe, effective treatments hitting the market. The guidance is official as of June 26, 2025, and companies can comment anytime, making it easier and clearer to fight Lyme disease early on.

No Economic Impacts Identified for this Document

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
6/26/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register